Delcath Systems (DCTH) Misses Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
Delcath Systems (DCTH) PT Raised to $20 at BTIG
August 6, 2024 4:57 AM EDTBTIG analyst Marie Thibault raised the price target on Delcath Systems (NASDAQ: DCTH) to $20.00 (from $16.00) while maintaining a Buy rating.
The analyst comments "The U.S. commercial launch is ramping quicker than we initially expected with Delcath Systems reporting total Q2 sales of $7.8M, including $6.6M from Hepzato and $1.2M from OUS Chemosat sales. This was well above consensus of $5.2M. Seven treating centers were active in the quarter, performing what we estimate were 36 combined... More



